Genmab — Regulatory Filings 2012

Dec 17, 2012

Company Announcement

-- HexaBody platform is a novel technology platform to potently enhance
antibody therapeutics
-- Multiple new business opportunities created
-- Additional details on technology platform to be provided today at Genmab’s
Post-ASH Seminar

Copenhagen, Denmark; December 17, 2012 – Genmab A/S (OMX: GEN) announced today
the addition of a new proprietary technology, the HexaBody™ platform, to its
suite of next generation antibody technologies. The HexaBody platform is a
novel technology that allows the creation of differentiated antibody
therapeutics by enhancing the natural target killing abilities of antibodies in
a fundamentally new way. The HexaBody platform will be used to create novel
differentiated antibody therapeutics, to improve the efficacy of existing
antibody products, and to potentially repurpose drug candidates that were
unsuccessful in previous clinical trials due to lack of potency.

“We are very excited about the multiple new business opportunities the HexaBody
platform may create. This innovative technology will provide Genmab and our
potential partners with the possibility to improve upon existing products and
thereby extend their life cycles. We believe the HexaBody platform provides
cutting edge technology and the opportunity to create fundamentally new
products, robustly enhance existing products, and to repurpose discontinued
products,” said Jan van de Winkel, Ph.D., Chief Executive Officer at Genmab.

The HexaBody platform will be further described today at Genmab’s Post-ASH
Seminar which can be viewed via webcast on our website www.genmab.com at 2:00PM
GMT / 3:00PM CET / 9:00AM EST. Webcast viewers may submit questions during the
Q&A portion of the live webcast via the webcast player or by dialing +44 20
3140 0722 (international participants) or +1 718 705 7514 (US participants) and
asking for the Genmab call.

About the HexaBody platform
The HexaBody platform is Genmab’s novel proprietary technology designed to
increase the potency of antibodies. Antibodies have a natural ability to
eliminate pathogens and tumor cells by various cytotoxic mechanisms. The
HexaBody platform strengthens the killing ability of antibodies while retaining
regular structure and specificity. The technology has the potential to enhance
antibody therapeutics for a broad range of applications in cancer and
infectious diseases.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody®, HexaBody™,
and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of
GlaxoSmithKline.

Company Announcement no. 40
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark